51.54
  Price1.32%   -0.69
(Pre-market: 53.67 +2.13 +4.13%)
May-16-22 02:23AM CRISPR (CRSP) Focuses on Pipeline Amid Lack of Marketed DrugsZacks Investment Research
May-14-22 06:30AM Here's the No. 1 Reason to Buy Vertex Pharmaceuticals NowThe Motley Fool
May-13-22 11:52AM Why Editas Medicine's Shares Fell 28.9% This WeekThe Motley Fool
11:45AM 2 Stocks With 75% to 183% Upside, According to Wall StreetThe Motley Fool
May-13-22 10:32AM These 5-Stock Samplers Have Gotten Whacked. And That's OKThe Motley Fool
May-12-22 04:19AM Why Cathie Wood's Flagship ETF Slumped This WeekThe Motley Fool
10:33AM CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70 Allogeneic CAR-T Therapy CTX130™ for Patients with T-cell Lymphoma at the Annual European Hematology Association (EHA) 2022 Hybrid CongressGlobeNewswire Inc.
May-10-22 02:23AM Why This Analyst Has 'Little Conviction' On CRISPR's Upcoming Trial DataBenzinga
10:30AM CRISPR Therapeutics (CRSP) Q1 Earnings & Sales Miss EstimatesZacks Investment Research
May-09-22 05:15AM CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research
May-06-22 10:37AM Vertex (VRTX) Q1 Earnings Lag, Sales Top, Expense View TweakedZacks Investment Research
May-04-22 08:00AM CRISPR Therapeutics to Present at the 2022 Bank of America Healthcare ConferenceGlobeNewswire Inc.
May-02-22 06:02AM 3 Beaten-Down Stocks That Could Deliver 5X Gains By 2030The Motley Fool
Apr-30-22 09:05AM 2 Biotech Stocks to Buy and Hold for 10 YearsThe Motley Fool
Apr-28-22 10:09AM Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022Benzinga
09:14AM What 4 Analyst Ratings Have To Say About CRISPR TherapeuticsBenzinga
Apr-27-22 09:18AM These 2 Stocks Carry a Lot of Risk, but Their Upside Is HugeThe Motley Fool
Apr-22-22 02:58AM CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?Zacks Investment Research
Apr-19-22 06:20AM 3 Ominous Reasons to Avoid This Biotech PioneerThe Motley Fool
Apr-14-22 10:03AM M&As in Spotlight With GSK Announcement: 3 Biotechs in FocusZacks Investment Research
08:00AM Is Now the Time to Bet on This Game-Changing Stock?The Motley Fool
Apr-13-22 10:45AM CRISPR Stocks Are Huge -- Here's Why They'll Get Even Bigger by 2030The Motley Fool
05:52AM Another Nasdaq Bear Market on the Way? 3 Great Stocks to Buy AnywayThe Motley Fool
Apr-12-22 04:01AM CRISPR Therapeutics Proposes New Appointment to the Board of DirectorsGlobeNewswire Inc.
Apr-07-22 04:01AM CRISPR Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswire Inc.
Apr-06-22 07:47AM Vertex (VRTX) Stock Rallies 27% in a Year: What Lies Ahead?Zacks Investment Research
Apr-01-22 12:17PM Vertex's (VRTX) Pain Candidate Meets Goal in Two StudiesZacks Investment Research
10:45AM Worried About Rising Interest Rates? These 2 Growth Stocks Could HelpThe Motley Fool
Mar-29-22 08:15AM Kala Pharmaceuticals (KALA) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research
Mar-26-22 01:49AM How to future-proof your stock investments and outperform the market at the same timeMarketWatch
08:00AM 3 Ultra-Popular Stocks That Could Soar 120%, 51%, and 109%, Wall Street SaysThe Motley Fool
Mar-25-22 11:55AM How to future-proof your stock investments and outperform the market at the same timeMarketWatch
Mar-23-22 08:28AM Vertex (VRTX) to Begin Pivotal Study on Kidney CandidateZacks Investment Research
06:30AM Missed Out on Moderna? My Best Biotech Stock to Buy and HoldThe Motley Fool
Mar-18-22 07:16AM 3 Cathie Wood Stocks to Buy and Hold for 10 YearsThe Motley Fool
Mar-17-22 11:30AM CRISPR Therapeutics AG (CRSP) Up 5.8% Since Last Earnings Report: Can It Continue?Zacks Investment Research
05:38AM BeiGene, Ltd. (BGNE) Soars 25.1%: Is Further Upside Left in the Stock?Zacks Investment Research
Mar-16-22 12:27PM Who Benefits From Amazon's Stock Split?The Motley Fool
10:37AM Is CRISPR Therapeutics Stock a Buy Now?The Motley Fool
Mar-14-22 06:05AM 3 No-Brainer Stocks to Buy With $1,000 Right NowThe Motley Fool
Mar-11-22 07:49AM Why CRISPR Therapeutics Stock Soared This WeekThe Motley Fool
12:23PM Intellia (NTLA) Depreciates 27% Over a Month: Here's WhyZacks Investment Research
Mar-08-22 05:31AM CRISPR Therapeutics Stock Surged Today: Is It a Buy?The Motley Fool
04:35AM CRISPR Therapeutics Announces Poster Presentation at the American Association for Cancer Research 2022 Annual MeetingGlobeNewswire Inc.
Mar-08-22 04:18AM Why CRISPR Therapeutics Stock Is Soaring TodayThe Motley Fool
Mar-03-22 06:15AM Can Biotech Stocks Provide Crypto-Like Growth for Your Portfolio?The Motley Fool
Mar-01-22 10:45AM 2 Stocks to Buy No Matter What Happens in MarchThe Motley Fool
05:52AM Should You Buy Stocks Now? Here's What Warren Buffett ThinksThe Motley Fool
Feb-16-22 11:48AM CRISPR Therapeutics (CRSP) Q4 Earnings Miss, Revenues Up Y/YZacks Investment Research
05:56AM 3 Biotech Stocks to Buy in FebruaryThe Motley Fool
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient. The company is also developing CTX101, a donor-derived gene-edited allogeneic CAR-T therapy targeting CD19-positive malignancies. In addition, it is developing earlier stage allogeneic CAR-T programs targeting B-Cell maturation antigen and CD70; hemoglobinopathies to treat other diseases, including Hurler Syndrome and severe combined immunodeficiency disease; programs that are in preclinical development for indications, including glycogen storage disease Ia and hemophilia; and programs targeting diseases of organ systems outside the liver, such as Duchenne muscular dystrophy and cystic fibrosis. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated Vertex Pharmaceuticals (Europe) Limited to develop, manufacture, commercialize, sell, and use therapeutics. The company also has research collaboration agreements with Neon Therapeutics for developing neoantigen-based therapeutic vaccines and T cell therapies; Massachusetts General Hospital Cancer Center to develop T cell therapies for cancer; and with the ViaCyte, Inc. for designing allogeneic cell therapies derived from gene edited human stem cells for use in the treatment of diabetes type 1, diabetes type 2, and insulin dependent diabetes. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
Cap:    |  Volume (24h):